arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Arcturus Therapeutics Holdings Inc.

ARCT Health Care Biotechnology: Pharmaceutical Preparations
$15.82
Today
as of Sep 4, 16:45 ET
Last 30 days +175.13% Jul 28 → Sep 04
$4.87 $8.06 $11.24 $14.43 $17.62 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$15.61
High
$16.02
Low
$15.40
Volume
$533,894
Avg Vol
$781,939
Mkt Cap
$312M
P/E (TTM)
—
Beta
—
52w High
$24.17
52w Low
$5.50
Div Yield
—
Shares Out
$28M

Recent Press Releases & News last 60 days · 9 items

Aug 31 · 20:01 PR Business Wire
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
Aug 27 · 13:55 Zacks
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?
Aug 12 · 01:04 MarketBeat
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline
▸ Show all 9 press releases & news Free account →

Overview

52-week range
$5.50
$24
55% of range
Avg surprise (last 3)
+51.0%
Avg reaction (last 2)
+1.5%
50% positive
Latest IV / EM
108%
EM ±16.9% · $15 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.98$-1.02$-0.05$0.91$1.87 Actual $1.87Actual $-1.98Actual $-0.61Actual $-1.00Actual $-0.64Actual $-0.26Actual $-0.52Est $-1.58Actual $-0.34Est $-1.11Actual $-0.49Actual $-0.95Est $-1.14Actual $-0.84 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-27M$-9M$8M$26M$44M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.84 — — — — financials
Thu May 7, 2026Mar/2026 $-0.95 $-1.14 +16.7% -82.7% -2.5% earnings
Tue Sep 30, 2025Sep 2025 $-0.49 — — — — financials
Mon Aug 11, 2025Jun/2025 $-0.34 $-1.11 +69.4% — — earnings
Mon May 12, 2025Mar/2025 $-0.52 $-1.58 +67.1% — +5.6% earnings
Mon Sep 30, 2024Sep 2024 $-0.26 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.64 — — — — financials
Sun Mar 31, 2024Mar 2024 $-1.00 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.61 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.98 — — — — financials
Fri Mar 31, 2023Mar 2023 $1.87 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$3M$2M—$17M$28M$29M—$42M
Cost of revenue————————
Gross profit————————
Operating income$-26M$-29M—$-17M$-12M$-17M—$-11M
Net income$-24M$-27M—$-13M$-9M$-14M—$-7M
EPS (diluted)$-0.84$-0.95—$-0.49$-0.34$-0.52—$-0.26

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$191M$211M$231M$180M$196M$217M$237M$237M
Inventory————————
Total current assets$197M$217M$241M$249M$275M$279M$306M$331M
Total assets$224M$245M$271M$282M$309M$332M$344M$371M
Long-term debt—————$15M——
Total liabilities$53M$54M$57M$58M$78M$98M$103M$109M
Total equity$172M$191M$214M$225M$231M$234M$241M$262M

Implied volatility — last 90 days

21%165%308%452%596% Jun 07 — IV 114% · EM ±15.8%Jun 08 — IV 117% · EM ±15.4%Jun 09 — IV 153% · EM ±19.2%Jun 10 — IV 157% · EM ±18.6%Jun 11 — IV 39% · EM ±4.3%Jun 12 — IV 168% · EM ±17.2%Jun 15 — IV 247% · EM ±17.9%Jun 16 — IV 59% · EM ±3.5%Jun 17 — IV 390% · EM ±16.3%Jun 19 — IV 75% · EM ±16.6%Jun 22 — IV 79% · EM ±16.6%Jun 23 — IV 85% · EM ±17.3%Jun 24 — IV 96% · EM ±19.3%Jun 25 — IV 86% · EM ±16.9%Jun 26 — IV 95% · EM ±18.2%Jun 29 — IV 81% · EM ±14.3%Jun 30 — IV 93% · EM ±16.0%Jul 01 — IV 91% · EM ±15.2%Jul 02 — IV 83% · EM ±13.4%Jul 03 — IV 86% · EM ±13.4%Jul 06 — IV 110% · EM ±15.3%Jul 07 — IV 102% · EM ±13.5%Jul 08 — IV 107% · EM ±13.4%Jul 09 — IV 100% · EM ±11.8%Jul 10 — IV 156% · EM ±17.2%Jul 13 — IV 192% · EM ±16.0%Jul 14 — IV 456% · EM ±33.0%Jul 15 — IV 596% · EM ±35.2%Jul 20 — IV 32% · EM ±7.5%Jul 21 — IV 22% · EM ±5.0%Jul 22 — IV 29% · EM ±6.7%Jul 23 — IV 166% · EM ±37.4%Jul 24 — IV 168% · EM ±37.1%Jul 27 — IV 96% · EM ±20.0%Jul 28 — IV 121% · EM ±24.8%Jul 29 — IV 110% · EM ±22.0%Jul 30 — IV 160% · EM ±31.2%Jul 31 — IV 236% · EM ±45.1%Aug 03 — IV 492% · EM ±87.1%Aug 04 — IV 229% · EM ±39.4%Aug 05 — IV 115% · EM ±19.2%Aug 07 — IV 71% · EM ±11.1%Aug 10 — IV 136% · EM ±18.8%Aug 13 — IV 113% · EM ±13.4%Aug 14 — IV 74% · EM ±8.2%Aug 17 — IV 213% · EM ±17.8%Aug 18 — IV 278% · EM ±20.1%Aug 19 — IV 191% · EM ±11.3%Aug 20 — IV 430% · EM ±18.0%Aug 24 — IV 114% · EM ±23.9%Aug 25 — IV 96% · EM ±19.7%Aug 26 — IV 107% · EM ±21.5%Aug 27 — IV 103% · EM ±20.1%Aug 28 — IV 97% · EM ±18.6%Aug 31 — IV 90% · EM ±16.0%Sep 01 — IV 106% · EM ±18.2%Sep 02 — IV 116% · EM ±19.4%Sep 03 — IV 97% · EM ±15.7%Sep 04 — IV 108% · EM ±16.9%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in